Details of the Drug
General Information of Drug (ID: DMMTJE3)
| Drug Name |
Zaragozic Acid D
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Zaragozic acid D; UNII-N34668EC9D; CHEMBL502872; N34668EC9D; 155179-14-9; BDBM50292414; (7S,11xi,12xi,14E)-2,7-Anhydro-3,4-di-C-carboxy-8,9,10,12,13,14,15-heptadeoxy-12-methyl-15-phenyl-L-glycero-D-altro-pentadec-14-en-7-ulo-7,4-furanosonic acid 11-acetate 5-octanoate; L-glycero-D-altro-Pentadec-14-en-7-ulo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13,14,15-heptadeoxy-12-methyl-15-phenyl-, 11-acetate 5-octanoate, (7S,11xi,12xi,14E)-
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 3 | Molecular Weight (mw) | 678.7 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.6 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 21 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 5 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 14 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


